Pharmaceutical - Markets & Marketing, Ipsen

Filter

Current filters:

Markets & MarketingIpsen

Popular Filters

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

18-12-2013

French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Teijin debuts Ipsen's Somatuline in Japan; Galenica deal for Maltofer and Uro-Vaxom in China

18-01-2013

Teijin Pharma, the core company of the Japanese Teijin Group (TYO: 3401) health care business, and French…

Asia-PacificChina Medical SystemGalenicaIpsenLicensingMaltoferMarkets & MarketingPharmaceuticalRare diseasesSomatulineTeijinUro-VaxomVifor Pharma

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

04-07-2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market…

AvastinBioSynthemaIpsenLutatheraMarkets & MarketingOncologyPharmaceuticalRocheSomatuline

French government delists certain Ipsen products

29-01-2012

French drugmaker Ipsen (Euronext: IPN) announced the French government’s decision to no longer reimburse…

EuropeGingko bilobaIpsenMarkets & MarketingNeurologicalPharmaceuticalRegulation

Back to top